Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

MedPro Safety Products, Helvoet Pharma Sign PFSS Joint Development Agreement

MedPro Safety Products, a developer of medication delivery and blood collection technologies, has entered into a joint development agreement (JDA) with Belgium-based Helvoet Pharma for the technical development and commercialisation of its pre-filled safety syringe (PFSS).

MedPro’s PFSS passive safety device is a pre-filled medicament delivery system that provides automatic safety feature deployment, reducing and potentially eliminating the risk of a needlestick injury.

The device can deliver a variety of biotech and pharmaceutical products to the patient’s bloodstream and is comprised of two parts: a standard glass cartridge that will act as both a pre-filled medicament reservoir and syringe plunger, and a plastic safety syringe that incorporates a fully passive (or automatic) safety deployment system.

As per the agreemant, the glass cartridge will be developed jointly with Helvoet, and inserted into the syringe at the point of use. The PFSS is designed to be compatible with existing filling technology for ease of adoption and operational efficiencies and the glass cartridge is consistent with current industry practice.

Walter Weller, president and COO, said: “Our system design provides unique passive safety functionality, and we expect to be able to deliver this product at a competitive price because of the design compatibility with current pharmaceutical industry practices. We are extremely pleased to be partnered with Helvoet in the design of the cartridge and its components. Helvoet is a world class company that maintains component design capabilities as a core competency.”

Craig Turner, CEO of MedPro Safety Products, said: “Helvoet will provide both critical design expertise, accelerating our time-to-market, and marketing expertise through their relationships with 19 of the top 20 pharmaceutical companies and with other leading system component providers. And, since our PFSS is not specific to a medicament compound or a specific pharmaceutical company, we believe we can gain accelerated and broader market acceptance than other non-passive solutions currently available in the market.”